According to a statement, the partnership between Wockhardt UK and Serum Life Sciences UK Ltd will help create a significant number of employment opportunities, along with the establishment of a new sterile filling and finishing facility in Wrexham, North Wales.
A Wockhardt unit has teamed up with a subsidiary of Serum Institute of India to set up a new vaccine factory in Wrexham, North Wales (UK). According to a statement, the partnership between Wockhardt UK and Serum Life Sciences UK Ltd will help create a significant number of employment opportunities, along with the establishment of a new sterile filling and finishing facility in Wrexham, North Wales.
The two parties have entered into a profit-sharing arrangement for this new manufacturing facility that will deliver 150 million additional vaccine doses of multiple vaccines.” This partnership between Serum Life Sciences and Wockhardt UK is a testament to the excellence and innovation both parties bring to the global vaccine market,” noted Wockhardt Chairman Habil Khorakiwala.
Wockhardt Managing Director and Global CEO Murtaza Khorakiwala said the deal signals the role the company will now play in the global delivery of multiple vaccines, protecting citizens from infectious diseases – potentially including those used to vaccinate against COVID-19.
“The partnership will play an important role in building long-term capacity in the UK. With this we want to further strengthen the resilience of the supply and support the worldwide roll-out of vaccines,” said Serum Life Sciences President Natasha Poonawalla. Wockhardt UK has manufactured a COVID-19 vaccine in partnership with the UK government and AstraZeneca. The partnership with Serum Life Sciences is in addition to the earlier agreement, the company said.
This post Wockhardt unit partners with subsidiary SII to set up vaccine plant in UK was original published at “https://www.financialexpress.com/healthcare/wockhardt-unit-partners-with-sii-subsidiary-to-set-up-vaccine-manufacturing-plant-in-uk/2466668/”
